Key Dates

Related Announcements

PAR-22-239 - Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice corrects the Application Types allowed for PAR-22-239, Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed).

The following section of PAR-22-239 has been corrected:

Part 2. Full Text of Announcement, Section II. Award Information

Currently reads:

Application Types Allowed

New
Resubmission

Corrected to read:

Application Types Allowed

New
 

Part 2. Full Text of Announcement, Section IV. Application and Submission Information, 2. Content and Form of Application Submission

Overall Component

PHS 398 Research Plan (Overall)

Currently reads:

Introduction to Application: For Resubmission applications, an Introduction to Application is required in the Overall component.

Corrected to read (in italics):

Introduction to Application: Not Applicable

All other aspects of PAR-22-239 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Behrous Davani Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6170
Email: [email protected]/">[email protected]

Laritza M. Rodriguez, M.D., Ph.D.
National Cancer Institute (NCI)
Telephone: (240) 276-5969
Email: [email protected]
 

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 301-496-8634
Email: [email protected]